154491-55-1
Chemical Structure
Beauveriolide I
- CAS No.: 154491-55-1
- Formula:C27H41N3O5
- Molecular Weight:487.63
IUPAC Name: (3R,6S,9S,13S)-9-benzyl-13-((S)-hexan-2-yl)-3-isobutyl-6-methyl-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetraone
InChIKey: ZKSLFHXTWGEITF-JIORRVSTSA-N
SMILES: O=C(N[C@H](C(N[C@@H]1CC(C)C)=O)C)[C@@H](NC(C[C@@](OC1=O)([H])[C@@H](C)CCCC)=O)CC2=CC=CC=C2
Biological Activity: Beauveriolide I is an ACAT/SOAT inhibitor. Beauveriolide I selectively inhibits macrophage cholesteryl ester synthesis, blocks cholesteryl ester recycling, reduces cholesterol concentration, lipid droplet accumulation, and post-lysosomal cholesterol metabolism, and promotes the degradation of cholesteryl esters preferentially over triglycerides. Beauveriolide I reduces amyloid β peptide secretion. Beauveriolide I exhibits insecticidal and weak antibacterial activities. Beauveriolide I can be used in research on atherosclerosis, Alzheimer's disease, and cancer[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Beauveriolide I | 99.60% | Beauveriolide I is an ACAT/SOAT inhibitor. Beauveriolide I selectively inhibits macrophage cholesteryl ester synthesis, blocks cholesteryl ester recycling, reduces cholesterol concentration, lipid droplet accumulation, and post-lysosomal cholesterol metabolism, and promotes the degradation of cholesteryl esters preferentially over triglycerides. Beauveriolide I reduces amyloid β peptide secretion. Beauveriolide I exhibits insecticidal and weak antibacterial activities. Beauveriolide I can be used in research on atherosclerosis, Alzheimer's disease, and cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Namatame I, et al. Antiatherogenic activity of fungal beauveriolides, inhibitors of lipid droplet accumulation in macrophages. Proceedings of the National Academy of Sciences of the United States of America. 2004 Jan 20;101(3):737-42.
- [2]. Nur EAA, et al. Screening for microbial potentiators of neutral lipid degradation in CHO-K1 cells. Drug discoveries & therapeutics. 2022 Dec 26;16(6):273-279.
- [3]. Mochizuki K, et al. The Structures of Bioactive Cyclodepsipeptides, Beauveriolides I and II, Metabolites of Entomopathogenic Fungi Beauveria sp. Bull Chem Soc Jpn. 1993 Oct;66(10):3041‑3046.
- [4]. Charria Girón E, et al. Chemical clues to infection: A pilot study on the differential secondary metabolite production during the life cycle of selected species. IMA fungus. 2025;16:e172651.
- [5]. Witter DP, et al. The natural products beauveriolide I and III: a new class of beta-amyloid-lowering compounds. Chembiochem : a European journal of chemical biology. 2009 May 25;10(8):1344-7.
- [6]. Wang X, et al. Genome mining and biosynthesis of the Acyl-CoA:cholesterol acyltransferase inhibitor beauveriolide I and III in Cordyceps militaris. Journal of biotechnology. 2020 Feb 10;309:85-91.
